Key facts
- This page summarizes Jonathan McNeill's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
- 11 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 13 Mar 2024, 06:04.
Jonathan McNeill - 08 Mar 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- DYN
- Reported as of
- 08 Mar 2024
- Net transaction value
- -$2,264,023
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2024, 06:04:07 UTC
- Prior SEC filing
- 11 Mar 2024
- Next SEC filing
- 17 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Scalzo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan McNeill filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 13 Mar 2024.
Change
- Previous filing in this sequence was filed on 11 Mar 2024.
- Current net transaction value: -$2,264,023.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DYN
transaction
Common Stock
Options Exercise
- Transaction value
- $477,321
- Shares
- +86,159
- Change %
- +61%
- Price
- $5.54
- Shares after
- 227,343
- Date
- 08 Mar 2024
- Ownership
- Direct
DYN
transaction
Common Stock
Options Exercise
- Transaction value
- $21,279
- Shares
- +3,841
- Change %
- +1.7%
- Price
- $5.54
- Shares after
- 231,184
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
DYN
transaction
Common Stock
Sale
- Transaction value
- $882,520
- Shares
- -34,663
- Change %
- -15%
- Price
- $25.46
- Shares after
- 196,521
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
DYN
transaction
Common Stock
Sale
- Transaction value
- $1,460,195
- Shares
- -54,648
- Change %
- -28%
- Price
- $26.72
- Shares after
- 141,873
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F2
DYN
transaction
Common Stock
Sale
- Transaction value
- $18,817
- Shares
- -689
- Change %
- -0.49%
- Price
- $27.31
- Shares after
- 141,184
- Date
- 08 Mar 2024
- Ownership
- Direct
- Footnotes
- F3
DYN
transaction
Common Stock
Options Exercise
- Transaction value
- $98,750
- Shares
- +17,825
- Change %
- +13%
- Price
- $5.54
- Shares after
- 159,009
- Date
- 11 Mar 2024
- Ownership
- Direct
DYN
transaction
Common Stock
Sale
- Transaction value
- $454,181
- Shares
- -17,825
- Change %
- -11%
- Price
- $25.48
- Shares after
- 141,184
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F4
DYN
transaction
Common Stock
Sale
- Transaction value
- $45,661
- Shares
- -1,776
- Change %
- -1.3%
- Price
- $25.71
- Shares after
- 139,408
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F5, F6, F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DYN
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -86,159
- Change %
- -87%
- Price
- $0.000000
- Shares after
- 12,309
- Date
- 08 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 86,159
- Exercise price
- $5.54
- Footnotes
- F8
DYN
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,841
- Change %
- Price
- $0.000000
- Shares after
- $17,825
- Date
- 08 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,841
- Exercise price
- $5.54
- Footnotes
- F9
DYN
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -17,825
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 11 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,825
- Exercise price
- $5.54
- Footnotes
- F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.25 to $27.19, inclusive.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.14 to $26.09, inclusive.
Footnote F5
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.67 to $25.81, inclusive.
Footnote F7
Includes 132,976 unvested RSUs.
Footnote F8
The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments beginning on October 31, 2020.
Footnote F9
The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved.